Venus Remedies Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Venus Remedies Limited Pharmaceutical Export Portfolio Dataset — 29 Products, $86.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Venus Remedies Limited — Pharmaceutical Exporter Profile (2026) | 29 Products, $86.4M Trade | TransData Nexus

Venus Remedies Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $86.4M Total Trade · DGFT Verified

Venus Remedies Limited is an Indian pharmaceutical exporter with a total trade value of $86.4M across 29 products in 6 therapeutic categories. Based on 3,586 verified export shipments from Indian Customs (DGFT) records, Venus Remedies Limited is the #1 Indian exporter in 4 products including Imipenem, Bleomycin, Vincristine. Top exports include Meropenem ($41.7M), Imipenem ($9.9M), Enoxaparin ($5.1M).

Venus Remedies Limited — Export Portfolio & Destination Treemap

Venus Remedies Limited pharmaceutical export portfolio — 29 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Venus Remedies Limited? — Company Overview & Market Position

Venus Remedies Limited, established on September 15, 1989, is a publicly listed Indian pharmaceutical company headquartered in Panchkula, Haryana. The company operates under the Corporate Identification Number (CIN) L24232CH1989PLC009705 and is registered with the Registrar of Companies, Chandigarh. It is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 526953 and on the National Stock Exchange (NSE) under VENUSREM. As of March 13, 2026, Venus Remedies Limited's stock price was ₹927.50, reflecting a market capitalization of approximately ₹12.40 billion.

In the fiscal year 2025, the company reported a revenue of ₹6.48 billion, marking an 8.5% increase from the previous year. The net income for the same period was ₹762.85 million, a significant 118.8% rise. Venus Remedies Limited employs approximately 1,298 professionals, underscoring its substantial workforce dedicated to pharmaceutical manufacturing and research.

What Does Venus Remedies Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Meropenem$41.7M 2

Product Portfolio — Top 29 by Export Value

Venus Remedies Limited exports 29 pharmaceutical products across 6 therapeutic categories. Market leader (#1 exporter) in 4 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Meropenem	Advanced Antibiotics	$41.7M	834	18.0%	3
2	Imipenem	Advanced Antibiotics	$9.9M	201	29.1%	1
3	Enoxaparin	Cardiovascular	$5.1M	182	2.4%	4
4	Ceftriaxone	Advanced Antibiotics	$4.0M	232	1.4%	15
5	Paclitaxel	Oncology	$3.2M	220	3.8%	6
6	Carboplatin	Oncology	$2.7M	123	3.8%	6
7	Vancomycin	Antibiotics	$2.2M	113	2.4%	9
8	Gemcitabine	Oncology	$2.2M	189	4.7%	9
9	Cisplatin	Oncology	$1.7M	121	12.9%	2
10	Oxaliplatin	Advanced Oncology	$1.5M	132	3.2%	8
11	Bleomycin	Advanced Oncology	$1.3M	144	21.7%	1
12	Irinotecan	Oncology	$1.3M	110	3.1%	5
13	Epirubicin	Advanced Oncology	$1.2M	56	18.7%	2
14	Doxorubicin	Oncology	$1.1M	100	1.6%	9
15	Etoposide	Oncology	$988.8K	139	9.1%	3
16	Methotrexate	Immunosuppressants	$921.0K	169	2.6%	7
17	Bortezomib	Advanced Oncology	$864.3K	44	4.0%	4
18	Docetaxel	Oncology	$829.1K	97	2.1%	10
19	Piperacillin	Advanced Antibiotics	$730.8K	37	0.8%	12
20	Ceftazidime	Advanced Antibiotics	$722.5K	73	6.8%	3
21	Pemetrexed	Advanced Oncology	$507.2K	42	1.8%	9
22	Vincristine	Oncology	$494.4K	93	24.4%	1
23	Cyclophosphamide	Oncology	$492.4K	13	2.5%	4
24	Topotecan	Advanced Oncology	$224.6K	30	6.0%	2
25	Dacarbazine	Advanced Oncology	$216.9K	45	11.9%	1
26	Cytarabine	Advanced Oncology	$186.7K	18	1.7%	9
27	Teicoplanin	Advanced Antibiotics	$134.1K	18	2.1%	6
28	Vinorelbine	Advanced Oncology	$89.7K	6	2.6%	6
29	Actinomycin	Advanced Oncology	$35.6K	5	1.2%	7

Venus Remedies Limited exports 29 pharmaceutical products across 6 therapeutic categories with a total export value of $86.4M. The company is the #1 Indian exporter in 4 products: Imipenem, Bleomycin, Vincristine, Dacarbazine. The top category is Advanced Antibiotics (66.2% of portfolio), followed by Oncology (17.3%), indicating a concentrated portfolio with the top 5 products accounting for 73.9% of total export value.

Venus Remedies Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Venus Remedies Limited operates state-of-the-art manufacturing facilities in Panchkula, Haryana, and Baddi, Himachal Pradesh, India. These facilities are certified by globally recognized standards, including EU-GMP and WHO-GMP, ensuring the highest quality and safety in their products. The company also has a manufacturing plant in Werne, Germany, further expanding its global production capabilities. These facilities specialize in the development and manufacturing of innovative and high-quality fixed-dosage injectable solutions, catering to a diverse range of therapeutic areas.

3Key Leadership

The leadership team at Venus Remedies Limited comprises seasoned professionals with extensive experience in the pharmaceutical industry. Pawan Chaudhary serves as the Chairman and Managing Director, overseeing the company's strategic direction and operations. Ashutosh Jain holds the position of Chief Executive Officer and Whole-Time Director, leading the company's legal and regulatory departments. Manu Chaudhary is the Joint Managing Director and Head of Research, Development, and Operations, playing a pivotal role in the company's R&D initiatives. Peeyush Jain serves as the Deputy Managing Director and Head of Indian Marketing Operations, focusing on expanding the company's market presence within India. Akshansh Chaudhary is the Chief Technology Officer and Executive Director, driving technological advancements and innovation within the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Venus Remedies Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Venus Remedies Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has secured over 500 marketing authorizations from both regulated and emerging markets, reflecting its robust global footprint. In the United States, Venus Remedies Limited has received Qualified Infectious Disease Product (QIDP) designation from the FDA for its novel antibiotic formulation VRP-034, highlighting its commitment to addressing antimicrobial resistance. The company's manufacturing facilities are certified by EU-GMP and WHO-GMP standards, ensuring compliance with stringent regulatory requirements in these regions.

2Emerging Markets

Venus Remedies Limited has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality is demonstrated by its WHO prequalification, which facilitates access to these markets by meeting international standards. This expansion is supported by the company's diverse portfolio of research products, both commercialized and in the pipeline, catering to the unique healthcare needs of these regions.

3Geographic Strategy

Venus Remedies Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Venus Remedies Limited has made significant strides in the U.S. market, with its novel antibiotic formulation VRP-034 receiving Qualified Infectious Disease Product (QIDP) designation from the FDA. This designation underscores the company's commitment to addressing critical healthcare challenges. The company's manufacturing facilities are registered with the FDA, and it has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), reflecting its active engagement in the U.S. pharmaceutical market. The facilities have undergone FDA inspections, ensuring compliance with U.S. regulatory standards.

2WHO & EU GMP

Venus Remedies Limited's manufacturing facilities hold certifications from the World Health Organization's Good Manufacturing Practices (WHO-GMP) and the European Union's Good Manufacturing Practices (EU-GMP). These certifications affirm the company's adherence to international quality standards, facilitating access to regulated markets and reinforcing its reputation for producing high-quality pharmaceutical products.

3CDSCO & Indian Regulatory

Venus Remedies Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Venus Remedies Limited operates in a competitive landscape with several key players in the pharmaceutical industry. In the injectable antibiotics segment, the company faces competition from global pharmaceutical giants such as Pfizer, Merck, and Novartis. However, Venus Remedies Limited distinguishes itself through its specialized focus on antimicrobial resistance and oncology, areas where it holds a leading position. The company's portfolio concentration, with the top five products accounting for 73.9% of its total export value, indicates a strategic focus on high-demand therapeutic areas.

2Key Differentiators

Venus Remedies Limited's key differentiators include its strong emphasis on research and development, particularly in the fields of antimicrobial resistance and oncology. The company has secured over 130 patents, reflecting its commitment to innovation. Additionally, Venus Remedies Limited's manufacturing facilities are certified by WHO-GMP and EU-GMP standards, ensuring compliance with international quality benchmarks. The company's diverse product portfolio, with a focus on injectable solutions, caters to a wide range of therapeutic areas, enhancing its market appeal.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Venus Remedies Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Venus Remedies Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $86.4 million USD and 3,586 shipments across 29 products in six therapeutic categories. The company's top five products—Meropenem, Imipenem, Enoxaparin, Ceftriaxone, and Paclitaxel—account for 73.9% of its total export value, indicating a consistent and reliable supply of these key products. The company's adherence to international quality standards, as evidenced by its WHO-GMP and EU-GMP certifications, further underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Venus Remedies Limited as a supplier:

FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA).

WHO-GMP Certification: Ensure the company holds Good Manufacturing Practices certification from the World Health Organization.

Frequently Asked Questions — Venus Remedies Limited

How many pharmaceutical products does Venus Remedies Limited export from India?

Venus Remedies Limited exports 29 pharmaceutical products across 6 therapeutic categories. The top exports are Meropenem ($41.7M), Imipenem ($9.9M), Enoxaparin ($5.1M), Ceftriaxone ($4.0M), Paclitaxel ($3.2M). Total export value is $86.4M.

What is Venus Remedies Limited's total pharmaceutical export value?

Venus Remedies Limited's total pharmaceutical export value is $86.4M, based on 3,586 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Venus Remedies Limited the #1 Indian exporter?

Venus Remedies Limited is the #1 Indian exporter in 4 products: Imipenem (29.1% market share), Bleomycin (21.7% market share), Vincristine (24.4% market share), Dacarbazine (11.9% market share).

What therapeutic categories does Venus Remedies Limited cover?

Venus Remedies Limited exports across 6 therapeutic categories. The largest are Advanced Antibiotics (66.2%, 6 products), Oncology (17.3%, 10 products), Advanced Oncology (7.1%, 10 products).

Get Full Venus Remedies Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.